These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38202030)

  • 1. Steady Decline of HBV DNA Load under NAs in Lymphoma Patients and a Higher Level of qAnti-HBc Predict HBV Reactivation.
    Liu Y; Nuersulitan R; Zhang C; Huo N; Li J; Song Y; Zhu J; Liu W; Zhao H
    J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202030
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients.
    Wang WX; Jia R; Gao YY; Liu JY; Luan JQ; Qiao F; Liu LM; Zhang XN; Wang FS; Fu J
    Front Immunol; 2022; 13():894410. PubMed ID: 35958609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations between serum hepatitis B surface antigen and hepatitis B core antibody titers and liver fibrosis in treatment-naïve CHB patients.
    Li MR; Zheng HW; Ma SM; Liu YY; Qie LX; Li JQ; Wang DH; Sun XL; Ren GF; Zheng YH; Wang YL; Dai EH
    J Chin Med Assoc; 2018 Dec; 81(12):1052-1059. PubMed ID: 30143430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of anti-HBc quantification in hepatitis B virus related acute-on-chronic liver failure.
    Li J; Gong QM; Xie PL; Lin JY; Chen J; Wei D; Yu DM; Han Y; Zhang XX
    J Gastroenterol Hepatol; 2021 May; 36(5):1291-1299. PubMed ID: 33091955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection.
    Song LW; Liu PG; Liu CJ; Zhang TY; Cheng XD; Wu HL; Yang HC; Hao XK; Yuan Q; Zhang J; Kao JH; Chen DS; Chen PJ; Xia NS
    Clin Microbiol Infect; 2015 Feb; 21(2):197-203. PubMed ID: 25658546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.
    Liao H; Liu Y; Li X; Wang J; Chen X; Zou J; Li Q; Liu L; Wang J; Huang B; Lu F; Xu D
    Antivir Ther; 2019; 24(2):105-115. PubMed ID: 30511941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas.
    Lan TY; Lin YC; Tseng TC; Yang HC; Kao JH; Cheng CF; Lee TJ; Huang SC; Lu CH; Li KJ; Hsieh SC
    Gut Liver; 2023 Mar; 17(2):288-298. PubMed ID: 36268584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy.
    Seto WK; Wong DK; Chan TS; Hwang YY; Fung J; Liu KS; Gill H; Lam YF; Cheung KS; Lie AK; Lai CL; Kwong YL; Yuen MF
    Am J Gastroenterol; 2016 Dec; 111(12):1788-1795. PubMed ID: 27644733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B.
    Li MR; Zheng HW; Lu JH; Ma SM; Ye LH; Liu ZQ; Zhang HC; Liu YY; Lv Y; Huang Y; Dai EH; Sun DX
    Oncotarget; 2017 Feb; 8(7):11063-11070. PubMed ID: 28052021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
    Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
    J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients.
    Tseng CW; Liu WC; Ko PH; Chen YC; Tseng KC; Chang TT
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum qAnti-HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg-positive immune active patients.
    Wang X; Gao X; Wu R; Chi X; Xu H; Guan Y; Jin Q; Niu J
    J Gastroenterol Hepatol; 2022 Sep; 37(9):1806-1814. PubMed ID: 35509262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients.
    Hu HH; Liu J; Chang CL; Jen CL; Lee MH; Lu SN; Wang LY; Quan Y; Xia NS; Chen CJ; Chen PJ; Yang HI
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):172-181.e1. PubMed ID: 29753083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.
    Hou FQ; Song LW; Yuan Q; Fang LL; Ge SX; Zhang J; Sheng JF; Xie DY; Shang J; Wu SH; Sun YT; Wei SF; Wang MR; Wan MB; Jia JD; Luo GH; Tang H; Li SC; Niu JQ; Zhou WD; Sun L; Xia NS; Wang GQ
    Theranostics; 2015; 5(3):218-26. PubMed ID: 25553110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
    Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
    J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.
    Oliveri F; Surace L; Cavallone D; Colombatto P; Ricco G; Salvati N; Coco B; Romagnoli V; Gattai R; Salvati A; Moriconi F; Yuan Q; Bonino F; Brunetto MR
    Liver Int; 2017 Nov; 37(11):1622-1631. PubMed ID: 28296013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
    Yang HC; Tsou HH; Pei SN; Chang CS; Chen JH; Yao M; Lin SJ; Lin J; Yuan Q; Xia N; Liu TW; Chen PJ; Cheng AL; Hsu C;
    J Hepatol; 2018 Aug; 69(2):286-292. PubMed ID: 29551710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust
    Zhang YL; Gao Y; Cao JL; Zhao JH; Zhang TY; Yang CL; Xiong HL; Wang YB; Ou SH; Cheng T; Chen CR; Yuan Q; Xia NS
    Emerg Microbes Infect; 2019; 8(1):724-733. PubMed ID: 31130075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.